| Study             | CR rate (95% CI) | ORR rate (95% CI) | Two-year OS rate (95% CI) | CRCAE grade 3-4 infection rate (95% CI) | CRCAE grade 3-4 bleeding rate (95% CI) | CRCAE grade 3-4 cardiac disorder rate (95% CI) | CRCAE grade 3-4 bleeding rate (95% CI) |
|-------------------|------------------|------------------|---------------------------|----------------------------------------|----------------------------------------|---------------------------------------------|----------------------------------------|
| Schenk            | 0.35 (0.27-0.42) | 0.35 (0.27-0.42) | Excluded                  | 0.66 (0.59-0.73)                      | 0.06 (0.02-0.10)                      | 0.12 (0.07-0.17)                            | 0.17 (0.12-0.23)                        |
| Müller-Tidow      | 0.48 (0.38-0.58) | 0.58 (0.48-0.68) | 0.42                      | Not reported                           | Not reported                           | Not reported                               | Not reported                           |
| Krug              | 0.58 (0.30-0.86) | 0.58 (0.30-0.86) | Unavailable*              | Not reported                           | Not reported                           | 0.08 (0.00-0.23)                           | Not reported                           |
| Scandura          | 0.57 (0.39-0.74) | 0.90 (0.62-0.83) | Excluded                  | Not reported                           | Not reported                           | Not reported                               | 0.30 (0.14-0.46)                       |
| Huang             | 0.60 (0.46-0.73) | 0.73 (0.61-0.85) | 0.44                      | 0.17 (0.07-0.28)                      | Not reported                           | Not reported                               | Not reported                           |
| Ye                | 0.55 (0.40-0.70) | 0.75 (0.62-0.88) | 0.45                      | 0.70 (0.56-0.84)                      | 0.28 (0.14-0.41)                      | 0.03 (0.00-0.07)                           | Not reported                           |
| Li                | 0.78 (0.69-0.87) | 0.82 (0.74-0.91) | 0.19                      | Not reported                           | Not reported                           | 0.01 (0.00-0.03)                           | Not reported                           |
| L²                 | 87.8%            | 93.4%            | 84.2%                     | 96.9%                                  | 88.5%                                  | 81.4%                                      | 51.3%                                  |
| Pooled estimate   | 0.55 (0.43-0.68) | 0.67 (0.49-0.84) | 0.37                      | 0.51 (0.18-0.85)                      | 0.16 (0.00-0.37)                      | 0.05 (0.00-0.11)                           | 0.21 (0.10-0.33)                       |
| Kanakasetty       | 0.21 (0.10-0.31) | 0.31 (0.19-0.43) | 0.08                      | Not reported                           | Not reported                           | Not reported                               | Not reported                           |
| Ren               | 0.22 (0.11-0.33) | 0.52 (0.38-0.66) | 0.25                      | Not reported                           | Not reported                           | Not reported                               | Not reported                           |
| Fili              | 0.31 (0.20-0.42) | 0.42 (0.30-0.54) | Unavailable*              | Not reported                           | Not reported                           | Not reported                               | Not reported                           |
| Almeida           | 0.37 (0.24-0.51) | 0.51 (0.37-0.65) | 0.31                      | Not reported                           | Not reported                           | Not reported                               | Not reported                           |
| Wu                | 0.20 (0.11-0.29) | 0.69 (0.58-0.79) | 0.17                      | 0.26 (0.09-0.26)                      | 0.07 (0.16-0.36)                      | 0 (0.01-0.13)                              | 0 (0)                                  |
| Dombret           | 0.34 (0.27-0.41) | 0.38 (0.31-0.45) | 0.16                      | Not reported                           | Not reported                           | Not reported                               | Not reported                           |
| Gupta             | 0.19 (0.11-0.28) | 0.28 (0.18-0.37) | 0.14                      | Not reported                           | Not reported                           | Not reported                               | Not reported                           |
| Sadashiv          | 0.20 (0.00-0.40) | 0.33 (0.09-0.57) | 0.17                      | 0.07                                  | 0.13                                  | Not reported                               | Not reported                           |
| van der Helm      | 0.35 (0.16-0.53) | 0.42 (0.23-0.61) | 0.35                      | Not reported                           | Not reported                           | Not reported                               | Not reported                           |
\[
\begin{array}{ccccccc}
\text{Al-Ali} & 0.05 & 0.075 & \text{Unavailable}^* & \text{Not reported} & \text{Not reported} & \text{Not reported} \\
& (-0.02-0.12) & (-0.01-0.16) & & & & \\
\text{Kantarjian} & 0.16 & 0.30 & 0.11 & 0.26 & \text{Not reported} & \text{Not reported} \\
& (0.11-0.20) & (0.24-0.36) & (0.07-0.15) & (0.20-0.31) & & \\
\text{Lee} & 0.13 & 0.55 & \text{Excluded} & \text{Not reported} & \text{Not reported} & \text{Not reported} \\
& (0.06-0.19) & (0.46-0.65) & & & & \\
\text{Cashen} & 0.26 & \text{Not reported} & 0.12 & 0.24 & \text{Not reported} & \text{Not reported} \\
& (0.14-0.37) & & (0.03-0.20) & (0.12-0.35) & & \\
\text{Fenaux} & 0.17 & 0.49 & 0.51 & \text{Not reported} & \text{Not reported} & \text{Not reported} \\
& (0.11-0.22) & (0.42-0.57) & (0.43-0.58) & & & \\
\hline
\hline
\text{Pooled estimate} & 0.22 & 0.42 & 0.21 & 0.23 & 0.08 & 0 & 0 \\
& (0.18-0.26) & (0.35-0.48) & (0.13-0.29) & (0.16-0.30) & (0.02-0.13) & & \\
\hline
\text{P value} & 0.000 & 0.000 & 0.000 & 0.000 & 0.084 & 0.053 & 0.000 \\
\end{array}
\]

* The survival curve reported in the study did not reach a two-year end point.

CR: complete response; CTCAE: common terminology criteria for adverse events; ORR: overall response; OS: overall survival.